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Normal tissue uptake values
Quality control
Purpose: [18F]-ﬂuorothymidine ([18F]-FLT) is a PET-tracer enabling in-vivo visualization and quantiﬁcation
of tumor cell proliferation. For qualitative and quantitative analysis, adequate knowledge of normal tissue
uptake is indispensable. This study aimed to quantitatively investigate baseline tracer uptake of blood pool,
lung, liver and bone marrow and their precision, and to assess the longitudinal effect of systemic treatment
on biodistribution.
Methods: 18F–FLT-PET(/CT) scans (dynamic or static) of 90 treatment-naïve oncological patients were
retrospectively evaluated. Twenty-three patients received double baseline scans, and another 39 patients were
also scanned early and late during systemic treatment with a tyrosine kinase inhibitor. Reproducible volume of
interest were placed in blood pool, lung, liver, and bone marrow. For semi-quantitative analysis, SUVmean,
SUVmax, and SUVpeak with several normalizations were derived.
Results: SUVs of basal lung, liver, and bone marrow were not signiﬁcantly different between averaged dynamic
and static images, in contrast with blood pool and apical lung. Highest repeatability was seen for liver
and bone marrow, with repeatability coefﬁcients of 18.6% and 20.4% when using SUVpeak. Systemic
treatment with TKIs both increased and decreased normal tissue tracer uptake at early and late time points
during treatment.
Conclusion: Simultaneous evaluation of liver and bone marrow uptake in longitudinal response studies may be
used to assess image quality, where changes in uptake outside repeatability limits should trigger investigators
to perform additional quality control on individual PET images.
Advances in knowledge: For [18F]-FLT PET images, liver and bone marrow have low intra-patient variability when
quantiﬁed with SUVpeak, but may be affected by systemic treatment.
Implications for patient care: In [18F]-FLT-PET response monitoring trials, liver and bone marrow uptake may be
used for quality control of [18F]-FLT PET images.d Nuclear M
ds. Tel.: +3
. This is an o© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
[18F]-ﬂuorothymidine ([18F]-FLT) is an [18F]-bound thymidine
analogue enabling visualization and quantiﬁcation of tumor cell
proliferation using positron emission tomography (PET) [1,2].
In contrast with [18F]-ﬂuorodeoxyglucose ([18F]-FDG), inﬂammatoryedicine, VU Univer-
1 20 4444214.
pen access article underprocesses are less of an issue for [18F]-FLT [3]. Previous research
investigating [18F]-FLT uptake as biomarker of response to treatment
has proven it to be a useful tracer for assessing or predicting
progression-free and disease-free survival for several types of cancer [4].
In oncological PET(/CT) studies, normal tissue uptake can be used
both qualitatively and quantitatively to assess malignancy of suspected
lesions. Typically, a lesion is considered malignant if tracer uptake
exceeds background uptake of surrounding tissue in qualitative visual
analysis. In addition, uptake values of reference tissues such as blood
or liver are used to normalize tumor uptake in semi-quantitativethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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when variability of uptake in normal tissues within patients is high,
TBR may become an unreliable parameter reﬂecting true tumor activity
rather poorly and obscuring discriminative value of quantitative PET.
Simpliﬁed measures, such as standardized uptake values (SUV) and
TBR have proven useful for response assessment using [18F]-FLT-PET/CT
[5]. However, to use SUV reliably one needs to control for technical
image ﬂaws, such asmistakesmade in injected activity [6]. Additionally,
in order to use these simpliﬁed methods during treatment,
biodistribution and pharmacokinetics may not change drastically over
time. Hence, an image quality control method is necessary to allow for
appropriate quantiﬁcation of tumor activity.
Much research has been performed into normal tissue uptake and its
intra-patient variability in [18F]-FDG-PET [7–10]. However, as the bio-
distribution of [18F]-FLT is inherently different to that of [18F]-FDG,
results from these studies cannot merely be assumed to be applicable
to [18F]-FLT-PET studies. As [18F]-FLT is establishing itself as a valuable
oncological PET-tracer, researchers and physicians should have knowledge
of its normal tissue uptake variability within and between patients.
In this study we aimed at deriving normal [18F]-FLT uptake values
and their precisions for several tissues and/or organs and to explore if
these could be used to assess image quality for individual scans and/or
longitudinally. As [18F]-FLT is often used in lung cancer patients, we
assessed the effect of tyrosine-kinase inhibitor (TKI) treatment on nor-
mal tissue uptake values in lung cancer patients. Tissues investigated
were lung, blood pool, liver, and bone marrow. Several SUV types
were investigated, with several volumes of distribution normalizations.
2. Materials and methods
2.1. Patients
Images of 90 patients scanned with [18F]-FLT-PET(/CT) at baseline
(i.e. while receiving no systemic treatment), were gathered from six
single-center study cohorts and investigated in a retrospective analysis.
One cohort of 28 patients with non-Hodgkin lymphoma (NHL)
consisted only of baseline scans [11]. Twenty-three out of 90 patients
received double baseline scans in order to assess intra-patient
variability, with head and neck cancer (n = 6), non-small cell lung
cancer (NSCLC; n = 9), and breast cancer (n = 8), [12,13]. In two
cohorts of patients with NSCLC, a total of 39 patients were, in addition
to the baseline scans, also scanned early (after approximately 1 week)
and late (one cohort after 4 and one cohort after 6 weeks) during
treatment with a TKI [5,14]. A description of the included study cohorts
is provided in Table 1. All included studies were approved by the
medical ethical committee of the respective research institutes and
patients gave informed consent for participation.
2.2. Image acquisition
For extensive descriptions of image acquisition methods we refer to
the included studies' primary publications. Reconstructionmethods and
scanning modes (i.e. dynamic and static) with acquisition times (post
injection) are summarized in Table 1. Static scanning was performedTable 1
Description of included cohorts. Frames of dynamic acquired images were averaged.
Ref Study type No. patients Cohort Rec
[11] Baseline 28 NHL BLO
[14] Treatment 30 NSCLC OS
[12] Repeatability 6 HNC OS
[12] Repeatability 9 NSCLC OS
[5] Treatment 9 NSCLC RA
[13] Repeatability 8 BC FBP
NHL = non-Hodgkin lymphoma; NSCLC = non-small cell lung cancer; HNC = head-and-nec
OS-TF = iterative time-of-ﬂight reconstruction; RAMLA = row-action maximum likelihood aapproximately 60 min post-injection of [18F]-FLT. Frames of dynamic
scans were averaged over 45–60 min, 45–65 min, and 50–60 min,
depending on available frame durations, to generate comparable static
images allowing evaluation of effect of uptake intervals on SUVs.
2.3. Quantitative image analysis
Volumes of interest (VOI) of ﬁxed size and shape were placed in
lung, liver, bone marrow, and ascending aorta. Within the lung, uptake
may be a function of variation in perfusion, air density, liver spill-in, and
diaphragmatic motion. Therefore, we placed 3 cm diameter spheres
apically aswell as basally. For blood pool, a VOI 2 or 4 voxels (depending
on voxel size) in diameterwith an axial length of 2 cmwas placed in the
ascending aorta, which was identiﬁed on low-dose CT or on dynamic
PET-images acquired shortly after injection of 18F–FLT. In six patients
with head and neck cancer the aorta was outside the ﬁeld of view, in
which case the left carotid artery was used. In liver, a 3 cm diameter
sphere was placed in the upper right lobe. Vertebrae were used to
quantify bone marrow uptake; both single and multiple (3) lower
thoracic vertebrae were delineated using circular VOIs (5 or 9 voxels,
depending on voxel size), avoiding the vertebral cortex. Tissues with
known or apparent disease were avoided.
From each VOI, SUVmean (mean SUV within the VOI), SUVmax
(maximum SUV value within the VOI), and SUVpeak (mean SUV
within a 12 mm diameter sphere positioned within the VOI to yield
the highest value) were extracted. SUV was calculated according to
the following equation:
SUV ¼ AC= ID=normalization factorð Þ½ ; ð1Þ
where AC= activity concentration (Bq/mL), ID= injected dose at time
of scanning (Bq). Normalization factors were bodyweight (BW;
kilogram), lean body mass (LBM; kilogram), and body surface
area (BSA; m2). The latter two were calculated according to the
following equations:
LBMmale ¼ 1:10weight‐128:0 weight=heightð Þ2 ð2Þ
LBMfemale ¼ 1:07weight‐148:0 weight=heightð Þ2 ð3Þ
BSA ¼ 0:007184weight0:425height0:725 ð4Þ
Normalization factorswere indicated as sufﬁx to SUV(e.g. SUVpeak-bw,
being the peak SUV normalized to bodyweight).
2.4. Statistical analysis
For baseline SUVs, mean with standard deviation (SD) was
calculated for (averaged) dynamic and static data, to illustrate SUVs as
a function of acquisition time. In addition, coefﬁcients of variation
(COV%) were calculated to describe variability of uptake values.
Shapiro–Wilks test was used to assess normality of data. For data with
skewed distribution, data were log-transformed for statistical analysis.
To assess differences between dynamic and static data for each SUVonstruction Scanner Acquisition Uptake interval
B-OS-TF PET/CT Static 60 min
EM PET Static 60 min
EM PET Dynamic 45–60 min
EM PET Dynamic 45–60 min
MLA PET/CT Dynamic 50–60 min
PET Dynamic 45–65 min
k cancer; BC = breast cancer; OSEM = ordered subset expectation maximization; BLOB-
lgorithm; FBP = ﬁltered back projection.
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independent samples t-test was applied to investigate differences
between the two samples. Additionally, we calculate reference
ranges using 5th–95th percentiles. Extreme outliers (b[Q1–3*IQR]
or N[Q3 + 3*IQR]) were censored for calculation of reference ranges.
The effect of age and gender on baseline uptake values were analyzed
using multivariate linear regression.
To investigate repeatability (i.e. intra-patient variability), repeatabil-
ity coefﬁcients (RC) were calculated. Relative differences and RCs were
calculated as follows:
Relative difference ¼ scan2‐scan1ð Þ= scan1þ scan2Þ=2ð Þ½  100 ð5Þ
RC ¼ 1:96  SD; ð6Þ
where the SD is taken from the relative differences.
To illustrate the effect of treatment on normal tissue uptake, relative
change of SUV was calculated using the following formula:
Relative change ¼ scan2‐scan1ð Þ=scan 1½  100 ð7Þ
Relative changes were described using mean ± SD. All statistical
analyses were performed using IBM SPSS v22.0 (Armonk, USA).
3. Results
3.1. Baseline uptake values
Baseline scanswere categorized into two groups to investigate tissue
uptake as function of uptake interval; one group consisted of dynamic
images (frames averaged 45/50 to 60/65 min p.i.) and one group of
static images (60 min p.i.).
The effects of age and gender on uptake values were analyzed in
multivariate analysis, while correcting for acquisition type (static or
dynamic). Age was only a signiﬁcant modiﬁer for lung SUVmax-bw
(p = 0.035–0.046). Gender was a signiﬁcant modiﬁer for all SUV
types of bone marrow (single vertebra), liver, and blood pool
when using LBM for normalization (p = 0.003–0.046). For bone
marrow (multiple vertebrae), gender was a modiﬁer for SUVmean-
LBM (p = 0.029). For lung, gender was a modiﬁer for SUVmean-bsa
and SUVpeak-bsa (p = 0.013–0.026).
Henceforth, the remainder of the paper will focus on results of
SUVpeak normalized to bodyweight. All other data can be found in the
supplemental data.
Table 2 contains average SUVpeak-bw, of all investigated tissues
(Supplemental Table 1 for SUVmean and SUVmax). No extreme outliers
were identiﬁed. Blood pool and apical lung SUVpeak were signiﬁcantly
different between averaged dynamic and static images (p = 0.001
and p = 0.041, respectively). In contrast, SUVpeak of basal lung, liver,
and bone marrow were not signiﬁcantly different between
dynamic and static images, for all normalization factors (p = 0.604,
p = 0.126, and p = 0.444–0.592, respectively). For bone marrow
using multiple vertebrae, only SUVmax was signiﬁcantly different be-
tween dynamic and static images, regardless of normalization factor
(p = 0.027–0.049).
The distribution of SUVpeak (COV%) is illustrated in Fig. 1 as a
function of dynamic and static images. COVs of blood pool and boneTable 2
Baseline SUVpeak-bw of blood pool, lung, liver, and bone marrow.
Blood pool Lung (apical) Lung (basal)
Dynamic 0.87 ± 0.20 0.67 ± 0.28 0.60 ± 0.24
Static 0.70 ± 0.17 0.55 ± 0.19 0.57 ± 0.24
p-value 0.001 0.041 0.604
Data from averaged dynamic image frames and static images are displayed separately. Signiﬁcmarrow between static and dynamic images were similar within 1%.
For apical and basal lung, COVs between dynamic and static images
were−8.8% and 1.7% different, respectively. For liver, COVs between
dynamic and static images were−10.8% different.
To further illustrate the differences in SUVbetween the averaged dy-
namic and static images, time-activity curves of mean uptake in the in-
vestigated tissues are displayed in Fig. 2 for a dynamic scan of a typical
patient. A gradual decrease in activity concentrations can be seen for
blood pool and lung. Notably, the time-activity curve of lung tissue
has a very similar shape to the blood pool curve, suggesting that it is
mainly blood poolwhich ismeasured in lung. A decrease in liver activity
is noted over time, which corresponds to the data in Table 2. Bonemar-
row seems to be increasing at 55 min p.i., but it could have reached a
plateau at 60 min p.i. since there were no signiﬁcant differences in
bone marrow SUVmean between averaged dynamic and static images.
Before deﬁning reference ranges for SUVs of whole-body static scans
(60min p.i.), differences in SUVs between the static PET and PET/CT co-
hort were investigated. For liver and bone marrow, signiﬁcant differ-
ences were found for SUVmean and SUVpeak (all normalizations;
p = 0.000–0.024), but not for SUVmax. For lung, signiﬁcant differences
were found for SUVmax (all normalizations; p = 0.000–0.005), but not
for SUVmean and SUVpeak. For blood pool, only PET/CT datawere avail-
able for the static scans. As differences in SUV between PET and PET/CT
static whole-body scans were observed, reference ranges were calculat-
ed for the hybrid PET/CT cohort only. Reference ranges for SUVpeak-bw
(Supplemental Table 2 for other SUVs) of whole body static PET/CT
scans 60 min post-injection were 0.44–1.04 for blood pool, 0.34–0.83
for lung (apical), 3.46–7.46 for liver, and 4.86–11.36 for bone marrow
(multiple vertebrae).
3.2. Repeatability
Intra-patient variability of normal tissue SUVs between double base-
line scans was investigated using RCs. There were no signiﬁcant dissim-
ilarities between the normalizations of each SUV, with differences in
RCs between normalizations ranging 0.03–0.80%. For all SUV types,
liver and bone marrow (multiple vertebrae) provided the lowest RCs.
Liver and bonemarrow (multiple vertebrae) SUVpeak-bw RCs were
18.6% and 20.4%, respectively. Blood pool, lung (apical and basal), and
bone marrow (single vertebrae) SUVpeak-bw RCs were 27.4%, 43.3%,
46.3%, and 24.3%, respectively (Supplemental Fig. 1 for other SUVs).
3.3. Longitudinal variability
Two cohorts of NSCLC patients were scanned at baseline, and early
(approximately 1 week) and late (4 or 6 weeks, respectively) after
starting treatment with TKIs. Since between the SUVs of late scans of
the two cohorts (at 4 and 6 weeks) no signiﬁcant differences in relative
changes frombaselinewere found, these datawere pooled together. For
one cohort blood pool could not be evaluated due to absence of co-
registered CT and early dynamic PET images [14]. In the other cohort
liver could not be evaluated due to the chest only scan trajectory [5].
Table 3 contains the mean relative changes of SUVpeak-bw during
systemic treatment (Supplemental Table 3 for SUVmean and SUVmax).
Early during treatment the smallest relative changes were observed for
blood pool (−1.24 ± 15.71%). In contrast, blood pool had the largest
relative changes late during treatment (7.89 ± 17.63%). It should beLiver Bone marrow (single) Bone marrow (multiple)
5.86 ± 2.15 6.42 ± 1.67 6.48 ± 1.69
4.76 ± 1.23 6.26 ± 1.70 6.80 ± 1.79
0.126 0.592 0.444
ant differences in bold.
Fig. 1. Coefﬁcients of variation (%) of SUVpeak-bw for all reference tissues determined on averaged dynamic and static images.
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early during treatment all tissues except blood pool demonstrated mean
increases in tracer uptake. Lung uptake increased most early during TKI
treatment (7.2±25.5% and14.8±35.0% for apical andbasal lung, respec-
tively), with the smallest relative changes late during treatment (−
1.23± 27.87% and 2.19± 34.16% for apical and basal lung, respectively).Fig. 2. Tissue time-activity curves for blood pool (A), lung (B), liver (C), and bonemarrow (D). Cu
pool and lung curves are displayed with a logarithmic y-axis to enhance visual interpretation.For further illustration, Fig. 3 exhibits relative changes of SUVs,
respectively, from baseline for all individual patients, in which
the large ranges of changes from baseline are clearly visible
(Supplemental Fig. 2 for absolute changes). For each tissue, the SUV
with optimal intra- and inter-patient variability is displayed. Fig. 4 illus-
trates images of two patients with aberrant increases in uptake (earlyrves are generated fromdynamic images of a typical patient, in this casewithNSCLC. Blood
Table 3
Relative change from baseline of SUVpeak-bw of reference tissues early and late during treatment with TKIs.
Blood pool Lung (apical) Lung (basal) Liver Bone marrow (single) Bone marrow (multiple)
Early −1.24 ± 15.71 7.19 ± 25.47 14.77 ± 35.04 7.26 ± 16.51 3.09 ± 18.07 3.82 ± 17.62
Late 7.89 ± 17.63 −1.23 ± 27.87 2.19 ± 34.16 6.13 ± 25.13 6.69 ± 29.93 7.24 ± 29.50
Results are relative changes (mean ± SD) from baseline, in percentages.
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respectively. Remarkably, these patients only demonstrated these
aberrant increases in one tissue type.
4. Discussion
[18F]-FLT is a PET tracer increasingly used in oncological response
assessment PET(/CT)-studies, providing a biomarker of tumor
proliferation for several types of cancer, such as NSCLC, head and neck
squamous cell carcinoma, and breast cancer [4]. The aims of this paper
on normal reference tissue uptake values of [18F]-FLT-PET(/CT) images
were to evaluate their inter- and intra-patient variability, and to
assess the longitudinal variability of these values during systemic
treatment with TKIs. In addition to the most commonly used reference
tissues, being liver and blood pool, we also investigated lung and bone
marrow uptake.
Knowledge of reference values of normal tissue is critical for
qualitative image analysis, where malignancy is suspected if lesion up-
take exceeds background uptake. Furthermore, in quantitative analysis
a TBRmay be used to distinguish between benign andmalignant lesions
and for measuring response to treatment. Additionally, reference tissue
uptake may be used to calculate a threshold for malignancy, as done for
[18F]-FDG-PET in the PERCIST criteria usingmean liver uptake [15]. Also,Fig. 3. Relative changes from baseline (%) early and late during treatment of NSCLC with TKI
(D, SUVpeak). Each line represents an individual patient. Blue and red lines indicate relative
optimal repeatability determined per tissue type (Fig. 3). For a patient in (B) relative change inreliability of (semi-)quantitative analysis of tumor tracer uptake is
affected by the technical quality with which a PET study is performed
[16,17]. Hence, a reliable reference valuewith low inter-patient variabil-
ity may serve as an image-based quality control method.
SUVmean, SUVmax, and SUVpeak have different characteristics re-
garding sensitivity to noise and inter- and intra-observer variability
caused by VOI placement [18,19]. Most commonly, in clinical practice
and clinical studies, SUVmax is used due to its low dependency on accu-
rate and reliable VOI placement and hence ease of applicability. Howev-
er, its sensitivity to noise level may render it an unreliable parameter of
normal tissue tracer uptake, especially inmulti-center studies. SUVpeak
seems an appropriate alternative in this context, due to its intrinsically
lower sensitivity to noise ﬂuctuations and similarly low dependency
on VOI placement. Lodge et al. found that for quantiﬁcation of primary
brain tumors SUVpeak indeed provided best repeatability at 60 min
post-injection, making it an attractive SUV for tumor quantiﬁcation
[20]. In this study, however, while intra-patient variabilitywas different
between SUV types, conclusions regarding the most reliable tissues
(liver and bone marrow) were similar regardless of SUV type.
Considering the intra-patient variability of normal tissue uptake
in this study, liver seems to be the most stable reference tissue
(Fig. 3). Remarkably, SUVmax demonstrated the lowest intra- and
inter-patient variability for this tissue. However, SUVpeak had verys of blood pool (A, SUVpeak), lung (B, SUVmean), liver (C, SUVpeak), and bone marrow
changes below and above repeatability coefﬁcients (%), respectively, for the SUV with
lung SUVmean of 209% exceeded the y-axis.
Fig. 4. Coronal 18F–FLT-PET images of two NSCLC patients demonstrating substantial increases in tracer uptake in bone marrow (A–C) and lung (D–F), respectively, early after starting
treatment with TKI. Images of baseline (A, D) and 1 week (B, E), and 4 weeks (C, F) after starting treatment. Images represent frames acquired at 50–60 min post-injection. Injected
activities were: A, 397 MBq; B, 375 MBq; C, 395 MBq; D, 350 MBq; E, 366 MBq; F, 378 MBq.
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image noise. The second lowest RCs were observed for bone marrow
SUVpeakwhen derived frommultiple vertebrae. Additionally, SUVpeak
was not different between averaged dynamic and static images for both
liver and bonemarrow (Table 2). Blood pool and lung SUVs seemed less
stable than liver and bonemarrow, and these tissues should not be used
as reference.
During treatment (with TKIs) we observed changes in
biodistribution larger than test–retest limits (Fig. 3), which could be a
consequence of altered tracer kinetics and/or metabolism during
systemic treatments. Drugs affecting glucuronidation of FLT in liver or
renal clearance of FLT may result in altered area-under-the-curves of
the arterial input functions. Also, drugs affecting tissue proliferation
(speciﬁcally bone marrow in this study) may explain these changes in
FLT uptake. The observed treatment-induced alterations in FLT kinetics
can explain why in previous research tumor-to-blood ratios seemed
most appropriate for assessment of treatment response in locally
advanced breast cancer and NSCLC, when correlated with full kinetic
modeling [5,21]. A rationale for this is that tumor SUVs ﬂuctuate with
blood pool activity, and use of tumor-to-blood ratios may compensate
for variations in arterial input functions. Overall, this emphasizes the
importance of dynamic PET/CT validation studies before SUVs can be
used for tumor quantiﬁcation during treatment.
Taken together, we recommend liver and bonemarrow to be used as
normal tissue references for [18F]-FLT-PET images. SUVpeak of these
tissues demonstrated good repeatability and was not affected by
differences in uptake intervals. Liver uptake can be easily quantiﬁed
by placing a 3 cm diameter spherical VOI in the right upper liver lobe
and measuring SUVpeak. For bone marrow quantiﬁcation we suggest
delineating three adjacent vertebrae, avoiding the vertebral cortex,
and measuring SUVpeak. We observed no signiﬁcant advantage of
using either bodyweight, lean body mass, or body surface area for SUV
normalization in this context. However, LBM and BSA may be affected
by gender type, thus using bodyweight is preferred.
As both liver and bonemarrow uptake can change during systematic
treatment a conservative approach could be to assess liver and bone
marrow and verify if these uptakes are within expected ranges and
remain constant during treatment. If this would not be the case it does
not necessarily imply poor image quality and/or poor execution of the
PET/CT study, but it could alert the observer to perform additional
quality control on the images such as veriﬁcation of injected activities,
uptake times and acquisition/reconstruction settings. Also it shouldalert the observer that there are changes in tracer uptake biodistribution
that may affect lesion uptake interpretation as well. The changed
biodistribution could namely also result from a change in arterial
input function as was shown before for tumor quantiﬁcation for [18F]-
FLT and [18F]-FDG [5,22].
This study has several limitations, among which the heterogeneity
between studies due to the retrospective nature. However, Kuhnert
et al. found that while different reconstructions provide different SUVs
for tumors, this was not the case for liver tissue [23]. This is probably
due to the fact that differences in noise and contrast between recon-
structions do not affect SUV of homogeneous tissue when using a
mean uptake value, such as SUVmean or SUVpeak. Despite heterogene-
ity between cohorts we were able to identify liver and bone marrow as
the most reliable reference tissues, with similar RCs as seen for tumor
SUVs [13]. In addition, perhaps a smaller reference range for liver and
bone marrow uptake can be determined in future studies performing
commonly used PET acquisitionmodes for 18F-FLT-PET images (i.e. stat-
ic whole body scans performed 60min after injection) with larger sam-
ple sizes.
5. Conclusion
We investigated blood pool, lung, liver, and bone marrow uptake of
[18F]-FLT -PET(/CT) images in oncological patients. Liver and bone
marrow seemed most appropriate for image-based quality control due
to high repeatability. However, clinicians should be aware of the
variable susceptibility of normal tissue SUVs to physiologic treatment
effects in patients undergoing systemic treatments. Simultaneous
evaluation of liver and bone marrow uptake in longitudinal response
studies may be used to assess image quality, where changes in SUVs
outside repeatability limits should trigger investigators to perform
additional quality control on individual PET images.
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